.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Accenture
Covington
Federal Trade Commission
US Army
Express Scripts
Cerilliant
Teva
Queensland Health
Dow

Generated: September 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Anti-CD324 monoclonal antibodies and uses thereof
Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
Inventor(s): Stull; Robert A. (Alameda, CA), Aujay; Monette (San Francisco, CA), Foord; Orit (Foster City, CA), Bankovich; Alex (San Francisco, CA), Hampl; Johannes (Santa Clara, CA), Dylla; Scott J. (Emerald Hills, CA), Liu; David (San Francisco, CA)
Assignee: ABBVIE STEMCENTRX LLC (North Chicago, IL)
Application Number:14/377,343
Patent Claims:1. An isolated anti-CD324 antibody or an antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof is selected from the group consisting of: a) an antibody comprising a light chain variable region set forth as SEQ ID NO: 20, and comprising a heavy chain variable region set forth as SEQ ID NO: 21; b) an antibody comprising a light chain variable region set forth as SEQ ID NO: 22, and comprising a heavy chain variable region set forth as SEQ ID NO: 23; c) an antibody comprising a light chain variable region set forth as SEQ ID NO: 24, and comprising a heavy chain variable region set forth as SEQ ID NO: 25; d) an antibody comprising a light chain variable region set forth as SEQ ID NO: 26, and comprising a heavy chain variable region set forth as SEQ ID NO: 27; e) an antibody comprising a light chain variable region set forth as SEQ ID NO: 28, and comprising a heavy chain variable region set forth as SEQ ID NO: 29; f) an antibody comprising a light chain variable region set forth as SEQ ID NO: 30, and comprising a heavy chain variable region set forth as SEQ ID NO: 31; g) an antibody comprising a light chain variable region set forth as SEQ ID NO: 32, and comprising a heavy chain variable region set forth as SEQ ID NO: 33; h) an antibody comprising a light chain variable region set forth as SEQ ID NO: 34, and comprising a heavy chain variable region set forth as SEQ ID NO: 35; i) an antibody comprising a light chain variable region set forth as SEQ ID NO: 36, and comprising a heavy chain variable region set forth as SEQ ID NO: 37; j) an antibody comprising a light chain variable region set forth as SEQ ID NO: 38, and comprising a heavy chain variable region set forth as SEQ ID NO: 39; k) an antibody comprising a light chain variable region set forth as SEQ ID NO: 40, and comprising a heavy chain variable region set forth as SEQ ID NO: 41; l) an antibody comprising a light chain variable region set forth as SEQ ID NO: 42, and comprising a heavy chain variable region set forth as SEQ ID NO: 43; m) an antibody comprising a light chain variable region set forth as SEQ ID NO: 44, and comprising a heavy chain variable region set forth as SEQ ID NO: 45; n) an antibody comprising a light chain variable region set forth as SEQ ID NO: 46, and comprising a heavy chain variable region set forth as SEQ ID NO: 47; o) an antibody comprising a light chain variable region set forth as SEQ ID NO: 48, and comprising a heavy chain variable region set forth as SEQ ID NO: 49; p) an antibody comprising a light chain variable region set forth as SEQ ID NO: 50, and comprising a heavy chain variable region set forth as SEQ ID NO: 51; q) an antibody comprising a light chain variable region set forth as SEQ ID NO: 52, and comprising a heavy chain variable region set forth as SEQ ID NO: 53; r) an antibody comprising a light chain variable region set forth as SEQ ID NO: 54, and comprising a heavy chain variable region set forth as SEQ ID NO: 55; s) an antibody comprising a light chain variable region set forth as SEQ ID NO: 56, and comprising a heavy chain variable region set forth as SEQ ID NO: 57; t) an antibody comprising a light chain variable region set forth as SEQ ID NO: 58, and comprising a heavy chain variable region set forth as SEQ ID NO: 59; u) an antibody comprising a light chain variable region set forth as SEQ ID NO: 60, and comprising a heavy chain variable region set forth as SEQ ID NO: 61; v) an antibody comprising a light chain variable region set forth as SEQ ID NO: 62, and comprising a heavy chain variable region set forth as SEQ ID NO: 63; w) an antibody comprising a light chain variable region set forth as SEQ ID NO: 64, and comprising a heavy chain variable region set forth as SEQ ID NO: 65; x) an antibody comprising a light chain variable region set forth as SEQ ID NO: 66, and comprising a heavy chain variable region set forth as SEQ ID NO: 67; y) an antibody comprising a light chain variable region set forth as SEQ ID NO: 68, and comprising a heavy chain variable region set forth as SEQ ID NO: 69; and z) an antibody comprising a light chain variable region set forth as SEQ ID NO: 70, and comprising a heavy chain variable region set forth as SEQ ID NO: 71.

2. The isolated anti-CD324 antibody or antigen binding fragment thereof according to claim 1, wherein the antibody or antigen binding fragment thereof is selected from the group consisting of: a) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 20 for CDR-L1, residues 50-56 of SEQ ID NO: 20 for CDR-L2, and residues 89-97 of SEQ ID NO: 20 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 21 for CDR-H1, residues 50-65 of SEQ ID NO: 21 for CDR-H2 and residues 95-102 of SEQ ID NO: 21 for CDR-H3, wherein the residues are numbered according to Kabat; b) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 22 for CDR-L1, residues 50-56 of SEQ ID NO: 22 for CDR-L2, and residues 89-97 of SEQ ID NO: 22 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 23 for CDR-H1, residues 50-65 of SEQ ID NO: 23 for CDR-H2 and residues 95-102 of SEQ ID NO: 23 for CDR-H3, wherein the residues are numbered according to Kabat; c) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 24 for CDR-L1, residues 50-56 of SEQ ID NO: 24 for CDR-L2, and residues 89-97 of SEQ ID NO: 24 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 25 for CDR-H1, residues 50-65 of SEQ ID NO: 25 or SEQ ID NO. 73 for CDR-H2 and residues 95-102 of SEQ ID NO: 25 for CDR-H3, wherein the residues are numbered according to Kabat; d) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 26 for CDR-L1, residues 50-56 of SEQ ID NO: 26 for CDR-L2, and residues 89-97 of SEQ ID NO: 26 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 27 for CDR-H1, residues 50-65 of SEQ ID NO: 27 for CDR-H2 and residues 95-102 of SEQ ID NO: 27 for CDR-H3, wherein the residues are numbered according to Kabat; e) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 28 for CDR-L1, residues 50-56 of SEQ ID NO: 28 for CDR-L2, and residues 89-97 of SEQ ID NO: 28 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 29 for CDR-H1, residues 50-65 of SEQ ID NO: 29 for CDR-H2 and residues 95-102 of SEQ ID NO: 29 for CDR-H3, wherein the residues are numbered according to Kabat; f) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 30 for CDR-L1, residues 50-56 of SEQ ID NO: 30 for CDR-L2, and residues 89-97 of SEQ ID NO: 30 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 31 for CDR-H1, residues 50-56 of SEQ ID NO: 31 for CDR-H2 and residues 95-102 of SEQ ID NO: 31 for CDR-H3, wherein the residues are numbered according to Kabat; g) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 32 for CDR-L1, residues 50-56 of SEQ ID NO: 32 for CDR-L2, and residues 89-97 of SEQ ID NO: 32 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 33 for CDR-H1, residues 50-56of SEQ ID NO: 33 for CDR-H2 and residues 95-102 of SEQ ID NO: 33 for CDR-H3, wherein the residues are numbered according to Kabat; h) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 34 for CDR-L1, residues 50-56 of SEQ ID NO: 34 for CDR-L2, and residues 89-97 of SEQ ID NO: 34 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 35 for CDR-H1, residues 50-65 of SEQ ID NO: 35 for CDR-H2 and residues 95-102 of SEQ ID NO: 35 for CDR-H3, wherein the residues are numbered according to Kabat; i) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 36 for CDR-L1, residues 50-56 of SEQ ID NO: 36 for CDR-L2, and residues 89-97 of SEQ ID NO: 36 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-34 of SEQ ID NO: 37 for CDR-H1, residues 50-65 of SEQ ID NO: 37 for CDR-H2 and residues 95-102 of SEQ ID NO: 37 for CDR-H3, wherein the residues are numbered according to Kabat; j) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 38 for CDR-L1, residues 50-56 of SEQ ID NO: 38 for CDR-L2, and residues 89-97 of SEQ ID NO: 38 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 39 for CDR-H1, residues 50-65 of SEQ ID NO: 39 for CDR-H2 and residues 95-102 of SEQ ID NO: 39 for CDR-H3, wherein the residues are numbered according to Kabat; k) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 40 for CDR-L1, residues 50-56 of SEQ ID NO: 40 for CDR-L2, and residues 89-97 of SEQ ID NO: 40 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 41 for CDR-H1, residues 50-65 of SEQ ID NO: 41 for CDR-H2 and residues 95-102 of SEQ ID NO: 41 for CDR-H3, wherein the residues are numbered according to Kabat; l) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 42 for CDR-L1, residues 50-56 of SEQ ID NO: 42 for CDR-L2, and residues 89-97 of SEQ ID NO: 42 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 43 for CDR-H1, residues 50-65 of SEQ ID NO: 43 for CDR-H2 and residues 95-102 of SEQ ID NO: 43 for CDR-H3, wherein the residues are numbered according to Kabat; m) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 44 for CDR-L1, residues 50-56 of SEQ ID NO: 44 for CDR-L2, and residues 89-97 of SEQ ID NO: 44 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 45 for CDR-H1, residues 50-65 of SEQ ID NO: 45 for CDR-H2 and residues 95-102 of SEQ ID NO: 45 for CDR-H3, wherein the residues are numbered according to Kabat; n) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 46 for CDR-L1, residues 50-56 of SEQ ID NO: 46 for CDR-L2, and residues 89-97 of SEQ ID NO: 46 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 47 for CDR-H1, residues 50-65 of SEQ ID NO: 47 for CDR-H2 and residues 95-102 of SEQ ID NO: 47 for CDR-H3, wherein the residues are numbered according to Kabat; o) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 48 for CDR-L1, residues 50-56 of SEQ ID NO: 48 for CDR-L2, and residues 89-97 of SEQ ID NO: 48 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 49 for CDR-H1, residues 50-65 of SEQ ID NO: 49 for CDR-H2 and residues 95-102 of SEQ ID NO: 49 for CDR-H3, wherein the residues are numbered according to Kabat; p) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 50 for CDR-L1, residues 50-56 of SEQ ID NO: 50 for CDR-L2, and residues 89-97 of SEQ ID NO: 50 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 51 for CDR-H1, residues 50-65 of SEQ ID NO: 51 for CDR-H2 and residues 95-102 of SEQ ID NO: 51 for CDR-H3, wherein the residues are numbered according to Kabat; q) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 52 for CDR-L1, residues 50-56 of SEQ ID NO: 52 for CDR-L2, and residues 89-97 of SEQ ID NO: 52 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 53 for CDR-H1, residues 50-65 of SEQ ID NO: 53 for CDR-H2 and residues 95-102 of SEQ ID NO: 53 for CDR-H3, wherein the residues are numbered according to Kabat; r) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 54 for CDR-L1, residues 50-56 of SEQ ID NO: 54 for CDR-L2, and residues 89-97 of SEQ ID NO: 54 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 55 for CDR-H1, residues 50-65 of SEQ ID NO: 55 for CDR-H2 and residues 95-102 of SEQ ID NO: 55 for CDR-H3, wherein the residues are numbered according to Kabat; s) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 56 for CDR-L1, residues 50-56 of SEQ ID NO: 56 for CDR-L2, and residues 89-97 of SEQ ID NO: 56 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 57 for CDR-H1, residues 50-65 of SEQ ID NO: 57 for CDR-H2 and residues 95-102 of SEQ ID NO: 57 for CDR-H3, wherein the residues are numbered according to Kabat; t) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 58 for CDR-L1, residues 50-56 of SEQ ID NO: 58 for CDR-L2, and residues 89-97 of SEQ ID NO: 58 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 59 for CDR-H1, residues 50-65 of SEQ ID NO: 59 for CDR-H2 and residues 95-102 of SEQ ID NO: 59 for CDR-H3, wherein the residues are numbered according to Kabat; u) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 60 for CDR-L1, residues 50-56 of SEQ ID NO: 60 for CDR-L2, and residues 89-97 of SEQ ID NO: 60 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 61 for CDR-H1, residues 50-65 of SEQ ID NO: 61 for CDR-H2 and residues 95-102 of SEQ ID NO: 61 for CDR-H3, wherein the residues are numbered according to Kabat; v) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 62 for CDR-L1, residues 50-56 of SEQ ID NO: 62 for CDR-L2, and residues 89-97 of SEQ ID NO: 62 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 63 for CDR-H1, residues 50-65 of SEQ ID NO: 63 for CDR-H2 and residues 95-102 of SEQ ID NO: 63 for CDR-H3, wherein the residues are numbered according to Kabat; w) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 64 for CDR-L1, residues 50-56 of SEQ ID NO: 64 for CDR-L2, and residues 89-97 of SEQ ID NO: 64 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 65 for CDR-H1, residues 50-65 of SEQ ID NO: 65 for CDR-H2 and residues 95-102 of SEQ ID NO: 65 for CDR-H3, wherein the residues are numbered according to Kabat; x) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 66 for CDR-L1, residues 50-56 of SEQ ID NO: 66 for CDR-L2, and residues 89-97 of SEQ ID NO: 66 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 67 for CDR-H1, residues 50-65 of SEQ ID NO: 67 for CDR-H2 and residues 95-102 of SEQ ID NO: 67 for CDR-H3, wherein the residues are numbered according to Kabat; y) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 68 for CDR-L1, residues 50-56 of SEQ ID NO: 68 for CDR-L2, and residues 89-97 of SEQ ID NO: 68 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 69 for CDR-H1, residues 50-65 of SEQ ID NO: 69 for CDR-H2 and residues 95-102 of SEQ ID NO: 69 for CDR-H3, wherein the residues are numbered according to Kabat; and z) an antibody comprising three light chain complementarity determining regions set forth as residues 24-34 of SEQ ID NO: 70 for CDR-L1, residues 50-56 of SEQ ID NO: 70 for CDR-L2, and residues 89-97 of SEQ ID NO: 70 for CDR-L3, and comprising three heavy chain complementarity determining regions set forth as residues 31-35 of SEQ ID NO: 71 for CDR-H1, residues 50-65 of SEQ ID NO: 71 for CDR-H2 and residues 95-102 of SEQ ID NO: 71 for CDR-H3, wherein the residues are numbered according to Kabat.

3. The isolated anti-CD324 antibody or antigen binding fragment thereof according to claim 2, wherein the antibody or antigen binding fragment thereof is selected from the group consisting of: a) an antibody comprising a light chain variable region set forth as SEQ ID NO: 20, and comprising a heavy chain variable region set forth as SEQ ID NO: 21; b) an antibody comprising a light chain variable region set forth as SEQ ID NO: 22, and comprising a heavy chain variable region set forth as SEQ ID NO: 23; c) an antibody comprising a light chain variable region set forth as SEQ ID NO: 24, and comprising a heavy chain variable region set forth as SEQ ID NO: 25; d) an antibody comprising a light chain variable region set forth as SEQ ID NO: 26, and comprising a heavy chain variable region set forth as SEQ ID NO: 27; e) an antibody comprising a light chain variable region set forth as SEQ ID NO: 28, and comprising a heavy chain variable region set forth as SEQ ID NO: 29; f) an antibody comprising a light chain variable region set forth as SEQ ID NO: 30, and comprising a heavy chain variable region set forth as SEQ ID NO: 31; g) an antibody comprising a light chain variable region set forth as SEQ ID NO: 32, and comprising a heavy chain variable region set forth as SEQ ID NO: 33; h) an antibody comprising a light chain variable region set forth as SEQ ID NO: 34, and comprising a heavy chain variable region set forth as SEQ ID NO: 35; i) an antibody comprising a light chain variable region set forth as SEQ ID NO: 36, and comprising a heavy chain variable region set forth as SEQ ID NO: 37; j) an antibody comprising a light chain variable region set forth as SEQ ID NO: 38, and comprising a heavy chain variable region set forth as SEQ ID NO: 39; k) an antibody comprising a light chain variable region set forth as SEQ ID NO: 40, and comprising a heavy chain variable region set forth as SEQ ID NO: 41; l) an antibody comprising a light chain variable region set forth as SEQ ID NO: 42, and comprising a heavy chain variable region set forth as SEQ ID NO: 43; m) an antibody comprising a light chain variable region set forth as SEQ ID NO: 44, and comprising a heavy chain variable region set forth as SEQ ID NO: 45; n) an antibody comprising a light chain variable region set forth as SEQ ID NO: 46, and comprising a heavy chain variable region set forth as SEQ ID NO: 47; o) an antibody comprising a light chain variable region set forth as SEQ ID NO: 48, and comprising a heavy chain variable region set forth as SEQ ID NO: 49; p) an antibody comprising a light chain variable region set forth as SEQ ID NO: 50, and comprising a heavy chain variable region set forth as SEQ ID NO: 51; q) an antibody comprising a light chain variable region set forth as SEQ ID NO: 52, and comprising a heavy chain variable region set forth as SEQ ID NO: 53; r) an antibody comprising a light chain variable region set forth as SEQ ID NO: 54, and comprising a heavy chain variable region set forth as SEQ ID NO: 55; s) an antibody comprising a light chain variable region set forth as SEQ ID NO: 56, and comprising a heavy chain variable region set forth as SEQ ID NO: 57; t) an antibody comprising a light chain variable region set forth as SEQ ID NO: 58, and comprising a heavy chain variable region set forth as SEQ ID NO: 59; u) an antibody comprising a light chain variable region set forth as SEQ ID NO: 60, and comprising a heavy chain variable region set forth as SEQ ID NO: 61; v) an antibody comprising a light chain variable region set forth as SEQ ID NO: 62, and comprising a heavy chain variable region set forth as SEQ ID NO: 63; w) an antibody comprising a light chain variable region set forth as SEQ ID NO: 64, and comprising a heavy chain variable region set forth as SEQ ID NO: 65; x) an antibody comprising a light chain variable region set forth as SEQ ID NO: 66, and comprising a heavy chain variable region set forth as SEQ ID NO: 67; y) an antibody comprising a light chain variable region set forth as SEQ ID NO: 68, and comprising a heavy chain variable region set forth as SEQ ID NO: 69; and z) an antibody comprising a light chain variable region set forth as SEQ ID NO: 70, and comprising a heavy chain variable region set forth as SEQ ID NO: 71.

4. The isolated anti-CD324 antibody or antigen binding fragment thereof according to claim 1, wherein the isolated anti-CD324 antibody or antigen binding fragment thereof is selected from the group consisting of monoclonal antibodies, chimeric antibodies, and humanized antibodies.

5. The isolated anti-CD324 antibody or antigen binding fragment thereof according to claim 2, comprising a light chain variable region set forth as SEQ ID NO: 72, and comprising a light chain variable region set forth as SEQ ID NO: 73.

6. The isolated anti-CD324 antibody or antigen binding fragment thereof according to claim 1, wherein the isolated anti-CD324 antibody or antigen binding fragment thereof is conjugated to a cytotoxic agent.

7. The isolated anti-CD324 antibody or antigen binding fragment thereof according to claim 5, wherein the isolated anti-CD324 antibody or antigen binding fragment thereof is conjugated to a cytotoxic agent.

8. A bispecific antibody comprising the antibody of claim 1 and an antibody that recognizes an epitope present on an antigen selected from the group consisting of OCT4, Nanog, STAT3, EPCAM, CD24, CD34, NB84, TrkA, GD2, CD133, CD20, CD56, CD29, B7H3, CD46, transferrin receptor, JAM3, carboxypeptidase M, oncostatin M, Lgr5, Lgr6, CD325, nectin-4, nestin, Soxl, Bmi-1, eed, easyhl, easyh2, mf2, yyl, smarcA3, smarckA5, smarcD3, smarcE1, m1lt3, DLL1, DLL4, FZD1, FZD2, FZD3, FZD4, FZD6, FZD7, FZD8, FZD9, FZD10, WNT2, WNT2B, WNT3, WNT5A, WNT10B, WNT16, AXIN1, BCL9, MYC, (TCF4) SLC7A8, SLC44A4, IL1RAP, TEM8, TMPRSS4, MUC16, GPRC5B, SLC6A14, SLC4A11, PPAP2C, CAV1, CAV2, PTPN3, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHA9, EPHB1, EPHB2, EPHB3, EPHB4, EPH5, EPHB6, EFNA1, EFNA2, EFNA3, EFNA5, EFNA6, EFNB1, EFNB2, EFNB3, SLC1A1, CX3CL1, ADORA2A, MPZL1, F1110052, C4.4A, EDG3, RARRES1, TMEPAI, PTS, CEACAM5, CEACAM6, NID2, STEAP, ABCA3, CRIM1, IL1R1, OPN3, DAF, MUC1, CPD, NMA, ADAMS, GJA1, SLC19A2, ABCA1, PCDH7, ADCY9, SLC39A1, NPC1, ENPP1, N33, GPNMB, LY6E, CELSR1, LRP3, C20orf52, TMEPAI, FLVCR, PCDHA10, GPR54, TGFBR3, SEMA4B, PCDHB2, ABCG2, CD166, AFP, BMP-4, .beta.-catenin, CD2, CD3, CD9, CD14, CD31, CD38, CD44, CD45, CD74, CD90, CXCR4, decorin, APCDD1, PTK7, EGFR, CD105, CD64, CD16, CD16a, CD16b, GLI1, GLI2, CD49b, CD49e and CD49f.

9. The bispecific antibody of claim 8, comprising the antibody of claim 1 and an antibody selected from the group consisting of abagovomab, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab, bivatuzumab, blinatumomab, brentuximab, cantuzumab, catumaxomab, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, daratumumab, drozitumab, duligotumab, dusigitumab, detumomab, dacetuzumab, dalotuzumab, ecromeximab, elotuzumab, ensituximab, ertumaxomab, etaracizumab, farletuzumab, ficlatuzumab, figitumumab, flanvotumab, futuximab, ganitumab, gemtuzumab, girentuximab, glembatumumab, ibritumomab, igovomab, imgatuzumab, indatuximab, inotuzumab, intetumumab, ipilimumab, iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab, lucatumumab, mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, moxetumomab, narnatumab, naptumomab, necitumumab, nimotuzumab, nofetumomabn, ocaratuzumab, ofatumumab, olaratumab, onartuzumab, oportuzumab, oregovomab, panitumumab, parsatuzumab, patritumab, pemtumomab, pertuzumab, pintumomab, pritumumab, racotumomab, radretumab, rilotumumab, rituximab, robatumumab, satumomab, sibrotuzumab, siltuximab, simtuzumab, solitomab, tacatuzumab, taplitumomab, tenatumomab, teprotumumab, tigatuzumab, tositumomab, trastuzumab, tucotuzumab, ublituximab, veltuzumab, vorsetuzumab, votumumab, zalutumumab, CC49 and 3F8.

10. A vector comprising a polynucleotide, wherein the polynucleotide encodes a polypeptide comprising a light chain variable region or a heavy chain variable region of an antibody according to claim 3.

Summary for Patent: ► Subscribe

PCT Information
PCT FiledFebruary 08, 2013PCT Application Number:PCT/US2013/025356
PCT Publication Date:August 15, 2013PCT Publication Number: WO2013/119960

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
RITUXAN
rituximab
VIAL1037050011997-11-26► Subscribe ABBVIE STEMCENTRX LLC (North Chicago, IL) Stull; Robert A. (Alameda, CA), Aujay; Monette (San Francisco, CA), Foord; Orit (Foster City, CA), Bankovich; Alex (San Francisco, CA), Hampl; Johannes (Santa Clara, CA), Dylla; Scott J. (Emerald Hills, CA), Liu; David (San Francisco, CA) ► SubscribeRXsearch
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe ABBVIE STEMCENTRX LLC (North Chicago, IL) Stull; Robert A. (Alameda, CA), Aujay; Monette (San Francisco, CA), Foord; Orit (Foster City, CA), Bankovich; Alex (San Francisco, CA), Hampl; Johannes (Santa Clara, CA), Dylla; Scott J. (Emerald Hills, CA), Liu; David (San Francisco, CA) ► SubscribeRXOrphansearch
Genzyme
CAMPATH
alemtuzumab
VIAL; INTRAVENOUS1039480012001-05-07► Subscribe ABBVIE STEMCENTRX LLC (North Chicago, IL) Stull; Robert A. (Alameda, CA), Aujay; Monette (San Francisco, CA), Foord; Orit (Foster City, CA), Bankovich; Alex (San Francisco, CA), Hampl; Johannes (Santa Clara, CA), Dylla; Scott J. (Emerald Hills, CA), Liu; David (San Francisco, CA) ► SubscribeRXOrphansearch
Genzyme
CAMPATH
alemtuzumab
VIAL; INTRAVENOUS1039480022001-05-07► Subscribe ABBVIE STEMCENTRX LLC (North Chicago, IL) Stull; Robert A. (Alameda, CA), Aujay; Monette (San Francisco, CA), Foord; Orit (Foster City, CA), Bankovich; Alex (San Francisco, CA), Hampl; Johannes (Santa Clara, CA), Dylla; Scott J. (Emerald Hills, CA), Liu; David (San Francisco, CA) ► SubscribeRXOrphansearch
Genzyme
LEMTRADA
alemtuzumab
INJECTABLE;INJECTION1039480032001-05-07► Subscribe ABBVIE STEMCENTRX LLC (North Chicago, IL) Stull; Robert A. (Alameda, CA), Aujay; Monette (San Francisco, CA), Foord; Orit (Foster City, CA), Bankovich; Alex (San Francisco, CA), Hampl; Johannes (Santa Clara, CA), Dylla; Scott J. (Emerald Hills, CA), Liu; David (San Francisco, CA) ► SubscribeRXOrphansearch
Imclone
ERBITUX
cetuximab
VIAL; INTRAVENOUS1250840012004-06-18► Subscribe ABBVIE STEMCENTRX LLC (North Chicago, IL) Stull; Robert A. (Alameda, CA), Aujay; Monette (San Francisco, CA), Foord; Orit (Foster City, CA), Bankovich; Alex (San Francisco, CA), Hampl; Johannes (Santa Clara, CA), Dylla; Scott J. (Emerald Hills, CA), Liu; David (San Francisco, CA) ► SubscribeRXOrphansearch
Genentech
AVASTIN
bevacizumab
VIAL; INTRAVENOUS1250850012004-02-26► Subscribe ABBVIE STEMCENTRX LLC (North Chicago, IL) Stull; Robert A. (Alameda, CA), Aujay; Monette (San Francisco, CA), Foord; Orit (Foster City, CA), Bankovich; Alex (San Francisco, CA), Hampl; Johannes (Santa Clara, CA), Dylla; Scott J. (Emerald Hills, CA), Liu; David (San Francisco, CA) ► SubscribeRXsearch
Genentech
AVASTIN
bevacizumab
VIAL; INTRAVENOUS1250850022004-02-26► Subscribe ABBVIE STEMCENTRX LLC (North Chicago, IL) Stull; Robert A. (Alameda, CA), Aujay; Monette (San Francisco, CA), Foord; Orit (Foster City, CA), Bankovich; Alex (San Francisco, CA), Hampl; Johannes (Santa Clara, CA), Dylla; Scott J. (Emerald Hills, CA), Liu; David (San Francisco, CA) ► SubscribeRXsearch
Amgen
VECTIBIX
panitumumab
INJECTABLE; IV (INFUSION)1251470012006-09-27► Subscribe ABBVIE STEMCENTRX LLC (North Chicago, IL) Stull; Robert A. (Alameda, CA), Aujay; Monette (San Francisco, CA), Foord; Orit (Foster City, CA), Bankovich; Alex (San Francisco, CA), Hampl; Johannes (Santa Clara, CA), Dylla; Scott J. (Emerald Hills, CA), Liu; David (San Francisco, CA) ► SubscribeRXsearch
Amgen
VECTIBIX
panitumumab
INJECTABLE; IV (INFUSION)1251470022006-09-27► Subscribe ABBVIE STEMCENTRX LLC (North Chicago, IL) Stull; Robert A. (Alameda, CA), Aujay; Monette (San Francisco, CA), Foord; Orit (Foster City, CA), Bankovich; Alex (San Francisco, CA), Hampl; Johannes (Santa Clara, CA), Dylla; Scott J. (Emerald Hills, CA), Liu; David (San Francisco, CA) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Express Scripts
Cantor Fitzgerald
Queensland Health
Julphar
Moodys
McKinsey
Novartis
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot